Murray Stahl's IONS Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 11,952 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $945,522, representing 0.01% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in IONS, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2023, adding 5,000 shares. Largest reduction occurred in Q3 2018, reducing 5,000 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -524 | Reduce 4.20% | 11,952 | $79.11 |
| Q3 2025 | +524 | Add 4.38% | 12,476 | $65.42 |
| Q2 2025 | -524 | Reduce 4.20% | 11,952 | $39.51 |
| Q4 2024 | +524 | Add 4.38% | 12,476 | $34.96 |
| Q3 2024 | -524 | Reduce 4.20% | 11,952 | $40.06 |
| Q4 2023 | -524 | Reduce 4.03% | 12,476 | $50.59 |
| Q1 2023 | +5,000 | Add 62.50% | 13,000 | $35.74 |
| Q1 2021 | -1,000 | Reduce 11.11% | 8,000 | $45.00 |
| Q4 2020 | -4,000 | Reduce 30.77% | 9,000 | $56.56 |
| Q2 2020 | +1,000 | Add 8.33% | 13,000 | $58.92 |
| Q1 2020 | -200 | Reduce 1.64% | 12,000 | $47.25 |
| Q3 2018 | -5,000 | Reduce 29.07% | 12,200 | $51.56 |
| Q4 2017 | -200 | Reduce 1.15% | 17,200 | $50.29 |
| Q3 2017 | +200 | Add 1.16% | 17,400 | $50.69 |
| Q2 2016 | +200 | Add 1.18% | 17,200 | $23.31 |
| Q4 2015 | +17,000 | New Buy | 17,000 | $61.94 |
Murray Stahl's Ionis Pharmaceuticals Investment FAQs
Murray Stahl first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2015, acquiring 17,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Ionis Pharmaceuticals, Inc. (IONS) for 41 quarters since Q4 2015.
Murray Stahl's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q4 2015, adding 17,000 shares worth $1.05 M.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 11,952 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $945,522.
As of the Q4 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 17,400 shares, as reported at the end of Q3 2017.